399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426